NT5E and neoplasm: GLUT1i treatment significantly reduced the CAF glycolytic metabolism (Fig. 4a and Supplementary Fig. 4a) and the number of CD73+ CD90+ glyCAF both at the tumor margin (Fig. 4b, c) and in the tumor mass (Fig. 4d).